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Abstract
POEMS syndrome is a rare multisystem disorder, chara -
cterized by the presence of polyneuropathy, organomega ly,
endocrinopathy, monoclonal protein and skin changes. 
The variety of clinical pictures and asynchronous manifes -
tation of dominant features make diagnosis difficult.
We report a case of a 42-year-old man with polyneuropa thy
who was initially negative for monoclonal protein and so 
Guillain-Barré syndrome was diagnosed. Other signs and
symptoms, including monoclonal gammopathy, developed
later in the course of the disease and finally POEMS syn-
drome was diagnosed.
Key words: POEMS syndrome, polyneuropathy, monoclo -
nal protein.
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CASE REPORT/OPIS PRZYPADKU
St reszc zen ie  
Zespó³ POEMS nale¿y do rzadkich chorób uk³adowych,
charakteryzuj¹cych siê wystêpowaniem polineuropatii, orga-
nomegalii, endokrynopatii, obecnoœci¹ bia³ka monoklonal-
nego i zmian skórnych. Ró¿norodny obraz kliniczny oraz nie-
wystêpowanie g³ównych objawów w jednym czasie znacznie
utrudniaj¹ i opóŸniaj¹ diagnostykê. 
W pracy przedstawiono przypadek 42-letniego mê¿czyzny
z obwodow¹ polineuropati¹, u którego pocz¹tkowo nie stwier-
dzono obecnoœci bia³ka monoklonalnego i rozpoznano zespó³
Guillaina-Barrègo. PóŸniej ujawni³y siê inne objawy i osta-
tecznie rozpoznano zespó³ POEMS.
S³owa kluczowe: zespó³ POEMS, polineuropatia, bia³ko
monoklonalne.
Introduction 
POEMS syndrome is a rare systemic disease. Other
names for the disease are Crow-Fukase syndrome, Taka t-
suki syndrome, and PEP osteosclerotic myeloma (plas-
ma cell dyscrasia, endocrinopathy, polyneuropathy) [1-3].
The acronym POEMS refers to major components of
this syndrome: polyneuropathy, organomegaly, endocrino -
pathy, monoclonal gammopathy (M protein) and skin
lesions. The term POEMS was used for the first time
by Bardwick in 1980 [4,5]. 
The highest risk of POEMS is in the fourth to sixth
decades of life, with men almost three times more like-
ly to be affected. The mean age of onset is 48 for men and
59 for women. Five-year survival is observed in appro -
ximately 60% of patients.
POEMS syndrome is one of the paraneoplastic syn-
dromes. It develops most often in the course of osteoscle-
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rotic (60%) and mixed (30%) myeloma. It can also co -
exist with systemic diseases such as systemic lupus ery-
thematosus [6].
Heterogeneous clinical onset without the simultaneous
occurrence of symptoms significantly interferes with diag-
nosis and makes diagnosis of POEMS difficult.
Case report 
A 42-year-old man was hospitalized for the first time
following a five-week history of persistent paraesthesias
of the hands and feet and progressive weakness of the low-
er limbs. His medical history was unremarkable. On
admission, neurological examination revealed diminished
upper limb tendon reflexes, paraparesis (more pronounced
distally – 3/5, than proximally – 4/5; the patient required
an aid to walk), impaired superficial sensation in the feet
and abolished tendon reflexes in the lower limbs.
The results of laboratory tests (blood count, bioche -
mi stry, coagulogram, proteinogram, serum thyroid hor-
mones, and vitamin B12 levels) were normal. Cerebro -
spinal fluid albumin-cytological dissociation was present
(protein 144 mg/dL, cytosis – 2 cells/μL). No mo no -
clonal protein was found in serum or spinal fluid.
Lumbo-sacral spine magnetic resonance imaging
(MRI) showed mild bulges of L4/L5 and L5/S1 inter-
vertebral discs without clinical significance. Previously
performed MRI of the thoracic spine revealed no ab nor-
malities. Electroneurography showed signs of demyeli-
nation as well as of axonal lesion of motor and sensory
nerves of upper and lower limbs (Table 1).
The patient fulfilled the clinical (progression of para-
paresis beyond 4 weeks), electrophysiological (prolong -
ed distal latencies and slowing of motor conduction velo -
cities) and laboratory (spinal fluid albumin-cytological
dissociation) criteria for Guillain-Barré syndrome [7].
Plasma exchange was introduced (five sessions) but with-
out any benefit. The patient was referred to the rehabili -
tation department for further treatment.
Four months later, the patient was once again admit-
ted to the Department of Neurology due to progressing
weakness of the lower and upper limbs and recurrent dys-
pnoea. Neurological examination revealed symmetrical
weakness of the upper (2/5) and lower (0/5) limbs, lack
of tendon reflexes in all extremities and diminished super-
ficial sensation in the hands and feet. Fundus examina-
tion showed bilateral papilloedema. Numerous skin lesions
of telangiectasia type as well as hyperpigmentation on the
chest and upper limbs were present. Severe oedema of
the legs was observed. The patient was subfebrile. A chest
computed tomography (CT) scan revealed bilateral ate-
lectatic and inflammatory changes, bilateral hydrothorax
and enlarged mediastinal lymph nodes. Antibiotics
were administered and – as shown by a subsequent CT
– pneumonia faded away, but some fluid in both pleu-
ral cavities and enlargement of the mediastinum persisted.
An ultrasound of the abdomen revealed hepatosple -
nomegaly and ascites. Cerebrospinal fluid total protein
level was significantly increased (418 mg/dL), but the
cytosis was normal (3 cells/μL). At that time, immunofi -
xation showed the presence of monoclonal protein (IgA,
lambda light chains) in serum, cerebrospinal fluid and
urine. The findings raised the suspicion of POEMS 
syndrome. Expanded diagnostics toward endocrinopathies
disclosed an elevated level of serum TSH (thyroid sti -
mulating hormone) (9.2 mU/L, normal = 0.27-4.2) and
Motor nerve conduction
Nerve Distal latency (ms) Conduction velocity (m/s) Amplitude (mV) F wave min. latency (ms)
Right median 4.0 35.5 4.9 43.8
Right ulnar 3.4 38.1 5.4 42.7
Left peroneal no response
Left tibial no response
Sensory nerve conduction
Nerve Conduction velocity (m/s) Amplitude (μV)
Right median 44.8 7.4
Right ulnar 34.3 2.3
Left sural 34.1 2.5
Table 1. Nerve conduction study results
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an increased level of free thyroid hormones FT4 
(6.4 pmol/L, normal = 12-22) and FT3 (2.67 pmol/L,
normal = 3.95-6.8). The substitution treatment of
hypothyroidism was started. The cause of the lower leg
oedema was not identified: lower limbs venal ultraso -
nography was unremarkable, and total serum protein and
albumins were within the normal range.
Bone marrow biopsy gave no evidence of any myelo-
proliferative disorder. Abdominal CT revealed a tumour,
probably metastatic, destroying the sacral bone. The pa -
tient did not agree to a tumour biopsy. He was refer red
for palliative treatment.
Discussion
To diagnose POEMS syndrome, it is necessary to
confirm the presence of polyneuropathy and monoclonal
gammopathy (both are considered to be major diagnostic
criteria). Moreover, at least one of the following minor
criteria must be present: sclerotic bone changes, orga -
nomegaly, endocrinopathy, Castleman disease, papillo -
edema, peripheral oedema, skin changes, hydrothorax or
ascites [1,2,4,8].
The presented patient finally fulfilled five minor diag-
nostic criteria, in addition to two obligatory major ones.
Other symptoms often observed in POEMS syn-
drome, although not included in the diagnostic criteria,
are blood disorders (thrombocytosis, polycythaemia), con-
gestive cardiomyopathy, pulmonary hypertension, obstruc-
tive pulmonary disease, thromboembolism, vitamin B12
deficiency, weight loss, excessive sweating, diarrhoea and
fever [9,10].
The pathomechanism responsible for the multi-
organ involvement in POEMS remains unclear. The im -
portant role of vascular endothelial growth factor
(VEGF) was suggested. Significantly elevated levels 
(in serum, but not in cerebrospinal fluid) of VEGF were
found in patients with POEMS and it may be respon-
sible for microangiopathy. Increased concentrations of 
pro inflammatory cytokines such as interleukin (IL)-1-β,
IL-6 and tu mour necrosis factor (TNF)-α were also
observed [8,11-14].
Monoclonal gammopathy, a disorder caused by the
uncontrolled proliferation of a single cell clone produc-
ing one class of immunoglobulin (M protein), is respon-
sible for approximately 10% of chronic acquired peri pheral
neuropathies in adults. It is therefore very important that
the panel of laboratory tests performed in patients with
acquired neuropathies should also include serum proteins
immunofixation. Multiple myeloma (with or without amy-
loidosis), osteosclerotic myeloma, primary systemic
amy loidosis, Waldenström macroglobulinaemia and
benign monoclonal gammopathy of undetermined sig-
nificance (MGUS) are the most common disorders
responsible for peripheral neuropathy related to mono-
clonal gammopathy [15,16]. Elevated CSF protein is
usually present in cases of polyneuropathy due to scle-
rotic myeloma and it can be observed also in Waldenström
macroglobulinaemia and MGUS [17]. In such cases
with motor or mixed symptomatology, Guillain-Barré 
syndrome and chronic inflammatory demyelinating poly -
neuropathy may be suspected.
Polyneuropathy in POEMS begins with sensory
symptoms and signs, most often affecting distal parts of
the upper and lower limbs. Later, ascending motor deficits
develop. Electrophysiological testing reveals both
demyelinating and axonal loss of motor and sensory fibres.
In the presented case, the acute onset as well as the
results of clinical, electrophysiological and laboratory eval-
uation, at first, strongly supported the diagnosis of Guil-
lain-Barré syndrome. At that time, monoclonal protein
was not found in serum and cerebrospinal fluid. 
In patients with POEMS syndrome, monoclonal pro-
tein is present primarily in serum (90-95%), rarely in cere-
brospinal fluid. It is an IgA or IgG class protein consisting
exclusively or almost exclusively of lambda light chains
[1,4,8]. The appearance of monoclonal protein in se rum
or other body fluids varies from case to case and it is some-
times considerably delayed in relation to other systemic
symptoms. On the other hand, the disappearance of mon-
oclonal protein in serum may lead to the withdrawal of
POEMS symptoms.
In reported cases of POEMS, it was a rule that when
clinical symptoms of neuropathy developed, monoclo nal
gammopathy was always present. It was exceptional in
our patient that during the initial evaluation, in spite of
severe incapacitating polyneuropathy, monoclonal pro-
tein was not found.
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